Concepedia

Author

Eytan M. Stein

Memorial Sloan Kettering Cancer CenterORCID

Also Known As

E M Stein, E Stein, E. M. Stein, E. Stein, E.M. Stein, ELLIOTT M. STEIN, Eytan M Stein, Eytan M. Stein, Eytan Stein, Mascarenhas, John

504

Publications

15.7K

Citations

49

H-Index

101

Concepts

All Affiliations

Memorial Sloan Kettering Cancer CenterThe University of Texas MD Anderson Cancer CenterDana-Farber Cancer InstituteMassachusetts General HospitalInstitut Gustave Roussy
EM

About

Eytan M. Stein is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

42

2.6K

2

Health Sciences

14

19

948

3

Natural Sciences

3

3

325

4

Nursing

2

2

22

5

Engineering

1

1

34

Eytan M. Stein

×

128

Publications

13.8K

Citations

43

H-Index

YearCitations

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum,

Blood

2022

2.7K

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea,

Blood

2017

1.4K

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton,

New England Journal of Medicine

2018

1.4K

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri,

Blood

2018

442

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio,

Nature

2023

420

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein,

Blood

2019

363

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Michael Amatangelo, Lynn Quek, Alan H. Shih,

Blood

2017

346

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi,

Blood

2018

323

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

Andrew M. Intlekofer, Alan H. Shih, Bo Wang,

Nature

2018

271

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Daniel A. Pollyea, Martin S. Tallman, Stéphane de Botton,

Leukemia

2019

235

Page 1